Similar articles

• Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.

  Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL. Chen LW, et al. J Gastroenterol Hepatol. 2010 Feb;25(2):259-63. doi: 10.1111/j.1440-1746.2009.06006.x. Epub 2009 Oct 9. J Gastroenterol Hepatol. 2010. PMID: 19817959
• Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.

  Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio PL, Di Marco V, Craxì A, Cacciola I, Squadrito G, Raimondo G. Ferraro D, et al. J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):172-5. J Biol Regul Homeost Agents. 2003. PMID: 14518718 Clinical Trial.
• Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?

  Hu KQ, Zhang YY. Hu KQ, et al. J Clin Gastroenterol. 2014 Jan;48(1):3-5. doi: 10.1097/MCG.0b013e3182a6633d. J Clin Gastroenterol. 2014. PMID: 24045272 No abstract available.
• Clinical practice. Chronic hepatitis C infection.

  Rosen HR. Rosen HR. N Engl J Med. 2011 Jun 23;364(25):2429-38. doi: 10.1056/NEJMcp1006613. N Engl J Med. 2011. PMID: 21696309 Review. No abstract available.
• [Treatment of chronic hepatitis C].

  Fehér J, Lengyel G. Fehér J, et al. Orv Hetil. 2004 May 16;145(20):1065-7. Orv Hetil. 2004. PMID: 15202329 Review. Hungarian. No abstract available.